Patents by Inventor Xiaohai Tang

Xiaohai Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250144252
    Abstract: Carbon nanoparticle suspension injection-Fe, a preparation method, an application and a use method. The carbon nanoparticle suspension injection-Fe includes carbon nanoparticle suspension injection and ferrous sulfate, where a concentration of the carbon nanoparticle suspension injection is 20-100 mg/mL, a concentration of ferrous ions in the carbon nanoparticle suspension injection-Fe is 0.5-60 mg/mL, and a particle size of carbon nanoparticles in the carbon nanoparticle suspension injection-Fe is 90-250 nm, and a pH value is 2.8-6.0. The carbon nanoparticle suspension injection-Fe serves as a developing agent after being injected into a tumor to show distribution of the carbon nanoparticle suspension injection-Fe and retention in the tumor on a magnetic resonance image.
    Type: Application
    Filed: December 5, 2024
    Publication date: May 8, 2025
    Inventors: Xiaohai Tang, Kexin Tang, Yuanfang Huang, Cheng Zeng
  • Publication number: 20230330135
    Abstract: The present disclosure claims a carbon nanoparticles suspension injection-Fe mixture. When the mixture is used in combination with near-infrared light for tumor low-temperature hyperthermia, the administration dosage can be decreased so as to reduce the occurrence of adverse reactions; the hyperthermia using the mixture has a low temperature, so that the surrounding normal tissues are not liable to be damaged, and the adverse reactions during the hyperthermia using carbon nanoparticles can also be reduced. Moreover, it is further proved that the CNSI-Fe mixture and the near-infrared irradiation are synergic. Based on the means and technical effects of low-temperature hyperthermia, the present disclosure has extensive clinical significance.
    Type: Application
    Filed: March 27, 2023
    Publication date: October 19, 2023
    Inventors: Xiaohai TANG, Kexin TANG, Yuanfang HUANG
  • Patent number: 11596643
    Abstract: The disclosure relates to a pectin-adriamycin conjugate, and discloses a preparation method and use of the conjugate above. The pectin-adriamycin conjugate of the disclosure has a completely new chemical structure and can be accumulated in a malignant tumor tissue for a long time with a high concentration in a targeting manner so as to achieve the purposes of enhancing effects and reducing toxicity, and the indications are chemotherapies of various solid malignant tumors.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: March 7, 2023
    Assignee: SICHUAN YINGRUI PHARMACEUTICAL TECHNOLOGY COMPANY
    Inventors: Xiaohai Tang, Cheng Zeng, Yuanfang Huang
  • Publication number: 20220110957
    Abstract: The disclosure relates to a pectin-adriamycin conjugate, and discloses a preparation method and use of the conjugate above. The pectin-adriamycin conjugate of the disclosure has a completely new chemical structure and can be accumulated in a malignant tumor tissue for a long time with a high concentration in a targeting manner so as to achieve the purposes of enhancing effects and reducing toxicity, and the indications are chemotherapies of various solid malignant tumors.
    Type: Application
    Filed: June 18, 2019
    Publication date: April 14, 2022
    Applicant: Sichuan Yingrui Pharmaceutical Technology Company
    Inventors: Xiaohai Tang, Cheng Zeng, Yuanfang Huang
  • Patent number: 11235976
    Abstract: The present invention provides a nanocarbon-iron composite system which is a composite structure formed by interaction of acid-treated nanocarbon serving as a carrier, with and ferrous ions and/or ferric ions in an iron salt. In an in-vitro experiment and an animal experiment, the nanocarbon-iron composite system of the present invention shows a very efficient inhibition effect on solid tumors containing liver cancer, breast cancer and cervical cancer and has an excellent targeting property. Accordingly, the present invention further provides a preparation method of the nanocarbon-iron composite system, use of the nanocarbon-iron composite system in preparation of a drug for treating solid tumors, and a suspension for injection based on the nanocarbon-iron composite system.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 1, 2022
    Assignee: SICHUAN YINGRUI PHARMACEUTICAL TECHNOLOGY COMPANY
    Inventors: Xiaohai Tang, Yu Qiu, Yuanfang Huang, Pingfang Xia
  • Publication number: 20190352183
    Abstract: The present invention provides a nanocarbon-iron composite system which is a composite structure formed by interaction of acid-treated nanocarbon serving as a carrier, with and ferrous ions and/or ferric ions in an iron salt. In an in-vitro experiment and an animal experiment, the nanocarbon-iron composite system of the present invention shows a very efficient inhibition effect on solid tumors containing liver cancer, breast cancer and cervical cancer and has an excellent targeting property. Accordingly, the present invention further provides a preparation method of the nanocarbon-iron composite system, use of the nanocarbon-iron composite system in preparation of a drug for treating solid tumors, and a suspension for injection based on the nanocarbon-iron composite system.
    Type: Application
    Filed: January 26, 2018
    Publication date: November 21, 2019
    Inventors: Xiaohai TANG, Yu QIU, Yuanfang HUANG, Pingfang XIA
  • Publication number: 20130172283
    Abstract: The invention belongs to the pharmaceutical field, and particularly relates to a lyophilized formulation of pectin-adriamycin conjugate and a preparation method thereof. In order to solve insolubility problem of the pectin-adriamycin conjugate (hereinafter referred to as PAC), improve bioavailability and facilitate preparation, the inventor prepared the PAC into a nanosuspension. However, as long-term stability of the nanosuspension is poor, the inventor proposed to prepare the nanosuspension into a lyophilized formulation, that is, an insoluble pectin-adriamycin conjugate is prepared into a suspension or nanosuspension, and a lyophilized support agent is added to the suspension for lyophilization treatment to prepare the lyophilized formulation. Lyophilized products prepared from the nanosuspension are characterized by enhanced stability of nano-particle size and enhanced stability of drug loading rate, which provides a new solution for clinical application of the PAC.
    Type: Application
    Filed: April 22, 2011
    Publication date: July 4, 2013
    Applicant: CHONGQING LUMMY PHARMACEUTICAL CO., LTD.
    Inventors: Xiaohai Tang, Yu Qiu
  • Publication number: 20120244193
    Abstract: The invention relates to a passive solid tumor-targeted anticancer prodrug and a preparation method thereof, belonging to the field of antitumor drugs. The preparation method includes the following steps: reacting low molecular weight pectin with Mw of 5,000-45,000 with doxorubicin to obtain a pectin-doxorubicin conjugate with Mw of 100,000-1,000,000, preparing the conjugate into a suspension, and treating the suspension in an ultra-high pressure nano homogenizer to obtain the passive solid tumor-targeted anticancer prodrug with particle size of 100 nm-200 nm and melting point of 220-245°, wherein the pectin and doxorubicin are linked by an amide bond, and the pectin is linked by an ester bond formed by condensing carboxyl groups and hydroxyl groups of pectin molecules. Cell inhibition rate of the anticancer prodrug for humanized lung cancer cells NCI-H446 and A549 is equivalent to that of doxorubicin hydrochloride.
    Type: Application
    Filed: May 19, 2010
    Publication date: September 27, 2012
    Applicant: CHONGQING LUMMY PHARMACEUTICAL CO., LTD.
    Inventors: Xiaohai Tang, Yu Qiu, Xin Song